Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 19/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6297506 | 0.98 | PDK2 (0.50) | PDK2KDM4EMEN1LMNAMAPT | |
| SCHEMBL29512055 | 0.98 | PDK2 (0.50) | PDK2KDM4EMEN1LMNAMAPT | |
| SCHEMBL29756478 | 0.98 | PDK2 (0.50) | PDK2KDM4EMEN1LMNAMAPT | |
| SCHEMBL416947 | 0.98 | PDK2 (0.50) | PDK2KDM4EMEN1LMNAMAPT | |
| SCHEMBL29424156 | 0.98 | PDK2 (0.50) | PDK2KDM4EMEN1LMNAMAPT | |
| SCHEMBL415665 | 0.98 | PDK2 (0.50) | PDK2KDM4EMEN1LMNAMAPT | |
| SCHEMBL5859559 | 0.96 | PDK2 (0.59) | PDK2MEN1LMNAMAPTKMT2A | |
| SCHEMBL4321761 | 0.96 | PDK2 (0.59) | PDK2MEN1LMNAMAPTKMT2A | |
| SCHEMBL25685038 | 0.96 | PDK2 (0.59) | PDK2MEN1LMNAMAPTKMT2A | |
| SCHEMBL5859662 | 0.96 | PDK2 (0.59) | PDK2MEN1LMNAMAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6861567-B2 | Spiro compounds, and their use | COVION ORGANIC SEMICONDUCTORS GMBH (DE) | 2005-03-01 | — | — | US | disclosed |
| EP-1053216-B1 | SPIRANS AND THE USE THEREOF | COVION ORGANIC SEMICONDUCTORS (DE) | 2003-09-10 | — | — | EP | disclosed |
| US-20030065190-A1 | Spiro compounds, and their use | MERCK OLED MATERIALS GMBH (DE) | 2003-04-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030065190-A1 | Spiro compounds, and their use | PKD1, REN, NR3C2 | PDK2 756/4885KDM4E 4514/4885MEN1 398/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.